Proteon crumbles after Phase III patency miss
Proteon Therapeutics Inc. (NASDAQ:PRTO) plummeted $7.40 (75%) to $2.50 after it said vonapanitase (formerly PRT-201) missed the primary endpoint in the Phase III PATENCY-1 trial in patients with chronic kidney disease (CKD). Compared to placebo, a single dose of vonapanitase failed to significantly improve primary unassisted patency, a measure of time to thrombosis or corrective procedure after creation of a fistula (p=0.254).
PATENCY-1 evaluated vonapanitase in patients receiving or expecting hemodialysis who underwent surgery for radiocephalic arteriovenous fistula creation. One year after surgery, primary unassisted patency was sustained at one year in 42% of patients receiving vonapanitase vs. 31% for placebo...
BCIQ Company Profiles
BCIQ Target Profiles